FDA Grants LOXO292 Breakthrough Designation for RET FusionPositive Thyroid Cancer

FDA Grants LOXO-292 Breakthrough Designation for RET Fusion-Positive Thyroid Cancer

The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options. 

More From BioPortfolio on "FDA Grants LOXO-292 Breakthrough Designation for RET Fusion-Positive Thyroid Cancer"